R-interferon treatment before imatinib reverses the negative impact of e13a2 transcript type on treatment free remission duration after tyrosine kinase inhibitors discontinuation in chronic myeloid leukemia patients Meeting Abstract
| Authors: | D'Adda, M.; Farina, M.; Passi, A.; Daffini, R.; Gramegna, D.; Cerqui, E.; Ferrari, S.; Bottelli, C.; Pagani, C.; Borlenghi, E.; Bertoli, D.; Archetti, S.; Marini, M.; Rossi, G. |
| Abstract Title: | R-interferon treatment before imatinib reverses the negative impact of e13a2 transcript type on treatment free remission duration after tyrosine kinase inhibitors discontinuation in chronic myeloid leukemia patients |
| Meeting Title: | 61st Annual Meeting and Exposition of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 134 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2019 Dec 7-10 |
| Meeting Location: | Orlando, FL |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2019-11-13 |
| Language: | English |
| ACCESSION: | WOS:000577164602169 |
| DOI: | 10.1182/blood-2019-125313 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 4146 -- Source: Wos |
